nodes	percent_of_prediction	percent_of_DWPC	metapath
Metipranolol—Lacrimation increased—Sunitinib—kidney cancer	0.0117	0.0118	CcSEcCtD
Metipranolol—Bronchitis—Temsirolimus—kidney cancer	0.0104	0.0105	CcSEcCtD
Metipranolol—Atrial fibrillation—Everolimus—kidney cancer	0.00986	0.00996	CcSEcCtD
Metipranolol—Conjunctivitis—Temsirolimus—kidney cancer	0.00941	0.0095	CcSEcCtD
Metipranolol—Epistaxis—Temsirolimus—kidney cancer	0.00913	0.00922	CcSEcCtD
Metipranolol—Acute coronary syndrome—Pazopanib—kidney cancer	0.00899	0.00908	CcSEcCtD
Metipranolol—Myocardial infarction—Pazopanib—kidney cancer	0.00894	0.00903	CcSEcCtD
Metipranolol—Rhinitis—Temsirolimus—kidney cancer	0.00872	0.0088	CcSEcCtD
Metipranolol—Epistaxis—Pazopanib—kidney cancer	0.00861	0.00869	CcSEcCtD
Metipranolol—Bradycardia—Pazopanib—kidney cancer	0.00834	0.00842	CcSEcCtD
Metipranolol—Angina pectoris—Vinblastine—kidney cancer	0.0079	0.00798	CcSEcCtD
Metipranolol—Angina pectoris—Everolimus—kidney cancer	0.00787	0.00794	CcSEcCtD
Metipranolol—Lacrimation increased—Paclitaxel—kidney cancer	0.00784	0.00792	CcSEcCtD
Metipranolol—Bronchitis—Everolimus—kidney cancer	0.00777	0.00784	CcSEcCtD
Metipranolol—Acute coronary syndrome—Vinblastine—kidney cancer	0.00713	0.0072	CcSEcCtD
Metipranolol—Acute coronary syndrome—Everolimus—kidney cancer	0.0071	0.00717	CcSEcCtD
Metipranolol—Myocardial infarction—Vinblastine—kidney cancer	0.00709	0.00716	CcSEcCtD
Metipranolol—Myocardial infarction—Everolimus—kidney cancer	0.00706	0.00713	CcSEcCtD
Metipranolol—Conjunctivitis—Everolimus—kidney cancer	0.007	0.00707	CcSEcCtD
Metipranolol—Acute coronary syndrome—Erlotinib—kidney cancer	0.00685	0.00692	CcSEcCtD
Metipranolol—Myocardial infarction—Erlotinib—kidney cancer	0.00681	0.00688	CcSEcCtD
Metipranolol—Epistaxis—Everolimus—kidney cancer	0.00679	0.00686	CcSEcCtD
Metipranolol—Conjunctivitis—Erlotinib—kidney cancer	0.00676	0.00682	CcSEcCtD
Metipranolol—Vision blurred—Pazopanib—kidney cancer	0.00672	0.00678	CcSEcCtD
Metipranolol—Cough—Temsirolimus—kidney cancer	0.0066	0.00667	CcSEcCtD
Metipranolol—Epistaxis—Erlotinib—kidney cancer	0.00656	0.00662	CcSEcCtD
Metipranolol—Hypertension—Temsirolimus—kidney cancer	0.00653	0.0066	CcSEcCtD
Metipranolol—Lacrimation—Doxorubicin—kidney cancer	0.0065	0.00656	CcSEcCtD
Metipranolol—Bronchitis—Sunitinib—kidney cancer	0.00649	0.00655	CcSEcCtD
Metipranolol—Rhinitis—Everolimus—kidney cancer	0.00648	0.00654	CcSEcCtD
Metipranolol—Myalgia—Temsirolimus—kidney cancer	0.00644	0.0065	CcSEcCtD
Metipranolol—Lacrimation increased—Capecitabine—kidney cancer	0.00643	0.0065	CcSEcCtD
Metipranolol—Anxiety—Temsirolimus—kidney cancer	0.00642	0.00648	CcSEcCtD
Metipranolol—Abnormal vision—Paclitaxel—kidney cancer	0.0063	0.00636	CcSEcCtD
Metipranolol—Cough—Pazopanib—kidney cancer	0.00622	0.00628	CcSEcCtD
Metipranolol—Oedema—Temsirolimus—kidney cancer	0.00618	0.00624	CcSEcCtD
Metipranolol—Acute coronary syndrome—Sorafenib—kidney cancer	0.00616	0.00622	CcSEcCtD
Metipranolol—Hypertension—Pazopanib—kidney cancer	0.00616	0.00621	CcSEcCtD
Metipranolol—Myocardial infarction—Sorafenib—kidney cancer	0.00613	0.00619	CcSEcCtD
Metipranolol—Myalgia—Pazopanib—kidney cancer	0.00607	0.00613	CcSEcCtD
Metipranolol—Acute coronary syndrome—Sunitinib—kidney cancer	0.00593	0.00599	CcSEcCtD
Metipranolol—Epistaxis—Sorafenib—kidney cancer	0.0059	0.00595	CcSEcCtD
Metipranolol—Oedema—Pazopanib—kidney cancer	0.00582	0.00587	CcSEcCtD
Metipranolol—Epistaxis—Sunitinib—kidney cancer	0.00568	0.00573	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Temsirolimus—kidney cancer	0.00563	0.00568	CcSEcCtD
Metipranolol—Atrial fibrillation—Paclitaxel—kidney cancer	0.00553	0.00559	CcSEcCtD
Metipranolol—Dyspnoea—Temsirolimus—kidney cancer	0.00551	0.00556	CcSEcCtD
Metipranolol—Bradycardia—Sunitinib—kidney cancer	0.0055	0.00555	CcSEcCtD
Metipranolol—Somnolence—Temsirolimus—kidney cancer	0.00549	0.00554	CcSEcCtD
Metipranolol—Vision blurred—Everolimus—kidney cancer	0.00531	0.00536	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Pazopanib—kidney cancer	0.0053	0.00535	CcSEcCtD
Metipranolol—Dyspnoea—Pazopanib—kidney cancer	0.00519	0.00524	CcSEcCtD
Metipranolol—Somnolence—Pazopanib—kidney cancer	0.00517	0.00522	CcSEcCtD
Metipranolol—Abnormal vision—Capecitabine—kidney cancer	0.00517	0.00522	CcSEcCtD
Metipranolol—Acute coronary syndrome—Vincristine—kidney cancer	0.00502	0.00506	CcSEcCtD
Metipranolol—Myocardial infarction—Vincristine—kidney cancer	0.00499	0.00504	CcSEcCtD
Metipranolol—Palpitations—Everolimus—kidney cancer	0.00497	0.00502	CcSEcCtD
Metipranolol—Cough—Everolimus—kidney cancer	0.00491	0.00496	CcSEcCtD
Metipranolol—Hypertension—Vinblastine—kidney cancer	0.00488	0.00493	CcSEcCtD
Metipranolol—Hypertension—Everolimus—kidney cancer	0.00486	0.00491	CcSEcCtD
Metipranolol—Myalgia—Everolimus—kidney cancer	0.00479	0.00484	CcSEcCtD
Metipranolol—Anxiety—Everolimus—kidney cancer	0.00478	0.00482	CcSEcCtD
Metipranolol—Acute coronary syndrome—Gemcitabine—kidney cancer	0.00476	0.0048	CcSEcCtD
Metipranolol—Discomfort—Vinblastine—kidney cancer	0.00475	0.0048	CcSEcCtD
Metipranolol—Cough—Erlotinib—kidney cancer	0.00474	0.00478	CcSEcCtD
Metipranolol—Discomfort—Everolimus—kidney cancer	0.00474	0.00478	CcSEcCtD
Metipranolol—Myocardial infarction—Gemcitabine—kidney cancer	0.00473	0.00478	CcSEcCtD
Metipranolol—Myalgia—Erlotinib—kidney cancer	0.00462	0.00467	CcSEcCtD
Metipranolol—Anxiety—Erlotinib—kidney cancer	0.00461	0.00465	CcSEcCtD
Metipranolol—Oedema—Everolimus—kidney cancer	0.00459	0.00464	CcSEcCtD
Metipranolol—Hypersensitivity—Temsirolimus—kidney cancer	0.00455	0.00459	CcSEcCtD
Metipranolol—Atrial fibrillation—Capecitabine—kidney cancer	0.00454	0.00459	CcSEcCtD
Metipranolol—Oedema—Erlotinib—kidney cancer	0.00443	0.00448	CcSEcCtD
Metipranolol—Asthenia—Temsirolimus—kidney cancer	0.00443	0.00447	CcSEcCtD
Metipranolol—Arthritis—Capecitabine—kidney cancer	0.00443	0.00447	CcSEcCtD
Metipranolol—Bronchitis—Paclitaxel—kidney cancer	0.00436	0.0044	CcSEcCtD
Metipranolol—Rhinitis—Gemcitabine—kidney cancer	0.00434	0.00439	CcSEcCtD
Metipranolol—Cough—Sorafenib—kidney cancer	0.00426	0.0043	CcSEcCtD
Metipranolol—Hypertension—Sorafenib—kidney cancer	0.00422	0.00426	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Everolimus—kidney cancer	0.00419	0.00423	CcSEcCtD
Metipranolol—Asthenia—Pazopanib—kidney cancer	0.00417	0.00421	CcSEcCtD
Metipranolol—Myalgia—Sorafenib—kidney cancer	0.00416	0.0042	CcSEcCtD
Metipranolol—Lacrimation increased—Doxorubicin—kidney cancer	0.00415	0.00419	CcSEcCtD
Metipranolol—Cough—Sunitinib—kidney cancer	0.0041	0.00414	CcSEcCtD
Metipranolol—Dyspnoea—Everolimus—kidney cancer	0.0041	0.00414	CcSEcCtD
Metipranolol—Somnolence—Everolimus—kidney cancer	0.00408	0.00412	CcSEcCtD
Metipranolol—Dizziness—Temsirolimus—kidney cancer	0.00408	0.00412	CcSEcCtD
Metipranolol—Hypertension—Sunitinib—kidney cancer	0.00406	0.0041	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Erlotinib—kidney cancer	0.00404	0.00408	CcSEcCtD
Metipranolol—Myalgia—Sunitinib—kidney cancer	0.004	0.00404	CcSEcCtD
Metipranolol—Acute coronary syndrome—Paclitaxel—kidney cancer	0.00398	0.00402	CcSEcCtD
Metipranolol—Myocardial infarction—Paclitaxel—kidney cancer	0.00396	0.004	CcSEcCtD
Metipranolol—Dyspnoea—Erlotinib—kidney cancer	0.00395	0.00399	CcSEcCtD
Metipranolol—Conjunctivitis—Paclitaxel—kidney cancer	0.00393	0.00397	CcSEcCtD
Metipranolol—Rash—Temsirolimus—kidney cancer	0.00389	0.00393	CcSEcCtD
Metipranolol—Dermatitis—Temsirolimus—kidney cancer	0.00389	0.00393	CcSEcCtD
Metipranolol—Headache—Temsirolimus—kidney cancer	0.00387	0.00391	CcSEcCtD
Metipranolol—Dizziness—Pazopanib—kidney cancer	0.00385	0.00388	CcSEcCtD
Metipranolol—Oedema—Sunitinib—kidney cancer	0.00384	0.00387	CcSEcCtD
Metipranolol—Epistaxis—Paclitaxel—kidney cancer	0.00381	0.00385	CcSEcCtD
Metipranolol—Myalgia—Dactinomycin—kidney cancer	0.00379	0.00383	CcSEcCtD
Metipranolol—Discomfort—Dactinomycin—kidney cancer	0.00374	0.00378	CcSEcCtD
Metipranolol—Bradycardia—Paclitaxel—kidney cancer	0.00369	0.00373	CcSEcCtD
Metipranolol—Rash—Pazopanib—kidney cancer	0.00367	0.0037	CcSEcCtD
Metipranolol—Nausea—Temsirolimus—kidney cancer	0.00367	0.0037	CcSEcCtD
Metipranolol—Dermatitis—Pazopanib—kidney cancer	0.00367	0.0037	CcSEcCtD
Metipranolol—Headache—Pazopanib—kidney cancer	0.00365	0.00368	CcSEcCtD
Metipranolol—Rhinitis—Paclitaxel—kidney cancer	0.00364	0.00367	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Sorafenib—kidney cancer	0.00363	0.00367	CcSEcCtD
Metipranolol—Oedema—Dactinomycin—kidney cancer	0.00363	0.00367	CcSEcCtD
Metipranolol—Angina pectoris—Capecitabine—kidney cancer	0.00362	0.00366	CcSEcCtD
Metipranolol—Bronchitis—Capecitabine—kidney cancer	0.00358	0.00361	CcSEcCtD
Metipranolol—Dyspnoea—Sorafenib—kidney cancer	0.00356	0.00359	CcSEcCtD
Metipranolol—Visual impairment—Paclitaxel—kidney cancer	0.0035	0.00353	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Sunitinib—kidney cancer	0.0035	0.00353	CcSEcCtD
Metipranolol—Nausea—Pazopanib—kidney cancer	0.00346	0.00349	CcSEcCtD
Metipranolol—Hypertension—Vincristine—kidney cancer	0.00343	0.00347	CcSEcCtD
Metipranolol—Dyspnoea—Sunitinib—kidney cancer	0.00342	0.00345	CcSEcCtD
Metipranolol—Hypersensitivity—Vinblastine—kidney cancer	0.0034	0.00343	CcSEcCtD
Metipranolol—Myalgia—Vincristine—kidney cancer	0.00339	0.00342	CcSEcCtD
Metipranolol—Hypersensitivity—Everolimus—kidney cancer	0.00338	0.00342	CcSEcCtD
Metipranolol—Abnormal vision—Doxorubicin—kidney cancer	0.00333	0.00337	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Dactinomycin—kidney cancer	0.00331	0.00334	CcSEcCtD
Metipranolol—Asthenia—Vinblastine—kidney cancer	0.00331	0.00334	CcSEcCtD
Metipranolol—Asthenia—Everolimus—kidney cancer	0.0033	0.00333	CcSEcCtD
Metipranolol—Cough—Gemcitabine—kidney cancer	0.00329	0.00332	CcSEcCtD
Metipranolol—Acute coronary syndrome—Capecitabine—kidney cancer	0.00327	0.0033	CcSEcCtD
Metipranolol—Hypertension—Gemcitabine—kidney cancer	0.00326	0.00329	CcSEcCtD
Metipranolol—Myocardial infarction—Capecitabine—kidney cancer	0.00325	0.00328	CcSEcCtD
Metipranolol—Oedema—Vincristine—kidney cancer	0.00325	0.00328	CcSEcCtD
Metipranolol—Conjunctivitis—Capecitabine—kidney cancer	0.00322	0.00326	CcSEcCtD
Metipranolol—Myalgia—Gemcitabine—kidney cancer	0.00321	0.00324	CcSEcCtD
Metipranolol—Asthenia—Erlotinib—kidney cancer	0.00318	0.00321	CcSEcCtD
Metipranolol—Discomfort—Gemcitabine—kidney cancer	0.00317	0.0032	CcSEcCtD
Metipranolol—Epistaxis—Capecitabine—kidney cancer	0.00313	0.00316	CcSEcCtD
Metipranolol—Tension—Paclitaxel—kidney cancer	0.0031	0.00313	CcSEcCtD
Metipranolol—Oedema—Gemcitabine—kidney cancer	0.00308	0.00311	CcSEcCtD
Metipranolol—Nervousness—Paclitaxel—kidney cancer	0.00307	0.0031	CcSEcCtD
Metipranolol—Dizziness—Vinblastine—kidney cancer	0.00305	0.00308	CcSEcCtD
Metipranolol—Dizziness—Everolimus—kidney cancer	0.00304	0.00307	CcSEcCtD
Metipranolol—Bradycardia—Capecitabine—kidney cancer	0.00303	0.00306	CcSEcCtD
Metipranolol—Rhinitis—Capecitabine—kidney cancer	0.00299	0.00301	CcSEcCtD
Metipranolol—Vision blurred—Paclitaxel—kidney cancer	0.00298	0.00301	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Vincristine—kidney cancer	0.00296	0.00299	CcSEcCtD
Metipranolol—Hypersensitivity—Sorafenib—kidney cancer	0.00294	0.00297	CcSEcCtD
Metipranolol—Dizziness—Erlotinib—kidney cancer	0.00293	0.00296	CcSEcCtD
Metipranolol—Rash—Everolimus—kidney cancer	0.0029	0.00292	CcSEcCtD
Metipranolol—Dermatitis—Everolimus—kidney cancer	0.00289	0.00292	CcSEcCtD
Metipranolol—Headache—Vinblastine—kidney cancer	0.00289	0.00292	CcSEcCtD
Metipranolol—Headache—Everolimus—kidney cancer	0.00288	0.00291	CcSEcCtD
Metipranolol—Visual impairment—Capecitabine—kidney cancer	0.00287	0.0029	CcSEcCtD
Metipranolol—Asthenia—Sorafenib—kidney cancer	0.00286	0.00289	CcSEcCtD
Metipranolol—Hypersensitivity—Sunitinib—kidney cancer	0.00283	0.00285	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.00281	0.00283	CcSEcCtD
Metipranolol—Rash—Erlotinib—kidney cancer	0.00279	0.00282	CcSEcCtD
Metipranolol—Dermatitis—Erlotinib—kidney cancer	0.00279	0.00282	CcSEcCtD
Metipranolol—Palpitations—Paclitaxel—kidney cancer	0.00279	0.00282	CcSEcCtD
Metipranolol—Headache—Erlotinib—kidney cancer	0.00278	0.0028	CcSEcCtD
Metipranolol—Cough—Paclitaxel—kidney cancer	0.00276	0.00278	CcSEcCtD
Metipranolol—Asthenia—Sunitinib—kidney cancer	0.00275	0.00278	CcSEcCtD
Metipranolol—Dyspnoea—Gemcitabine—kidney cancer	0.00275	0.00277	CcSEcCtD
Metipranolol—Nausea—Vinblastine—kidney cancer	0.00274	0.00277	CcSEcCtD
Metipranolol—Somnolence—Gemcitabine—kidney cancer	0.00274	0.00276	CcSEcCtD
Metipranolol—Nausea—Everolimus—kidney cancer	0.00273	0.00275	CcSEcCtD
Metipranolol—Hypertension—Paclitaxel—kidney cancer	0.00273	0.00275	CcSEcCtD
Metipranolol—Myalgia—Paclitaxel—kidney cancer	0.00269	0.00271	CcSEcCtD
Metipranolol—Anxiety—Paclitaxel—kidney cancer	0.00268	0.00271	CcSEcCtD
Metipranolol—Hypersensitivity—Dactinomycin—kidney cancer	0.00268	0.0027	CcSEcCtD
Metipranolol—Discomfort—Paclitaxel—kidney cancer	0.00266	0.00268	CcSEcCtD
Metipranolol—Dizziness—Sorafenib—kidney cancer	0.00264	0.00266	CcSEcCtD
Metipranolol—Nausea—Erlotinib—kidney cancer	0.00263	0.00266	CcSEcCtD
Metipranolol—Asthenia—Dactinomycin—kidney cancer	0.00261	0.00263	CcSEcCtD
Metipranolol—Oedema—Paclitaxel—kidney cancer	0.00258	0.0026	CcSEcCtD
Metipranolol—Dizziness—Sunitinib—kidney cancer	0.00254	0.00256	CcSEcCtD
Metipranolol—Rash—Sorafenib—kidney cancer	0.00251	0.00254	CcSEcCtD
Metipranolol—Dermatitis—Sorafenib—kidney cancer	0.00251	0.00254	CcSEcCtD
Metipranolol—Headache—Sorafenib—kidney cancer	0.0025	0.00252	CcSEcCtD
Metipranolol—Atenolol—ABCB1—kidney cancer	0.00247	0.261	CrCbGaD
Metipranolol—Vision blurred—Capecitabine—kidney cancer	0.00244	0.00247	CcSEcCtD
Metipranolol—Rash—Sunitinib—kidney cancer	0.00242	0.00244	CcSEcCtD
Metipranolol—Dermatitis—Sunitinib—kidney cancer	0.00242	0.00244	CcSEcCtD
Metipranolol—Headache—Sunitinib—kidney cancer	0.0024	0.00243	CcSEcCtD
Metipranolol—Hypersensitivity—Vincristine—kidney cancer	0.00239	0.00241	CcSEcCtD
Metipranolol—Nausea—Sorafenib—kidney cancer	0.00237	0.00239	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.00235	0.00237	CcSEcCtD
Metipranolol—Angina pectoris—Doxorubicin—kidney cancer	0.00234	0.00236	CcSEcCtD
Metipranolol—Asthenia—Vincristine—kidney cancer	0.00233	0.00235	CcSEcCtD
Metipranolol—Bronchitis—Doxorubicin—kidney cancer	0.00231	0.00233	CcSEcCtD
Metipranolol—Dyspnoea—Paclitaxel—kidney cancer	0.0023	0.00232	CcSEcCtD
Metipranolol—Somnolence—Paclitaxel—kidney cancer	0.00229	0.00231	CcSEcCtD
Metipranolol—Palpitations—Capecitabine—kidney cancer	0.00229	0.00231	CcSEcCtD
Metipranolol—Rash—Dactinomycin—kidney cancer	0.00229	0.00231	CcSEcCtD
Metipranolol—Nausea—Sunitinib—kidney cancer	0.00228	0.0023	CcSEcCtD
Metipranolol—Acebutolol—ABCB1—kidney cancer	0.00228	0.241	CrCbGaD
Metipranolol—Cough—Capecitabine—kidney cancer	0.00226	0.00228	CcSEcCtD
Metipranolol—Hypertension—Capecitabine—kidney cancer	0.00224	0.00226	CcSEcCtD
Metipranolol—Asthenia—Gemcitabine—kidney cancer	0.00221	0.00223	CcSEcCtD
Metipranolol—Myalgia—Capecitabine—kidney cancer	0.00221	0.00223	CcSEcCtD
Metipranolol—Anxiety—Capecitabine—kidney cancer	0.0022	0.00222	CcSEcCtD
Metipranolol—Discomfort—Capecitabine—kidney cancer	0.00218	0.0022	CcSEcCtD
Metipranolol—Nausea—Dactinomycin—kidney cancer	0.00216	0.00218	CcSEcCtD
Metipranolol—Dizziness—Vincristine—kidney cancer	0.00215	0.00217	CcSEcCtD
Metipranolol—Oedema—Capecitabine—kidney cancer	0.00212	0.00214	CcSEcCtD
Metipranolol—Conjunctivitis—Doxorubicin—kidney cancer	0.00208	0.0021	CcSEcCtD
Metipranolol—Rash—Vincristine—kidney cancer	0.00205	0.00207	CcSEcCtD
Metipranolol—Dermatitis—Vincristine—kidney cancer	0.00204	0.00206	CcSEcCtD
Metipranolol—Headache—Vincristine—kidney cancer	0.00203	0.00205	CcSEcCtD
Metipranolol—Epistaxis—Doxorubicin—kidney cancer	0.00202	0.00204	CcSEcCtD
Metipranolol—Bradycardia—Doxorubicin—kidney cancer	0.00195	0.00197	CcSEcCtD
Metipranolol—Rash—Gemcitabine—kidney cancer	0.00194	0.00196	CcSEcCtD
Metipranolol—Dermatitis—Gemcitabine—kidney cancer	0.00194	0.00196	CcSEcCtD
Metipranolol—Headache—Gemcitabine—kidney cancer	0.00193	0.00195	CcSEcCtD
Metipranolol—Nausea—Vincristine—kidney cancer	0.00193	0.00195	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.00193	0.00195	CcSEcCtD
Metipranolol—Rhinitis—Doxorubicin—kidney cancer	0.00192	0.00194	CcSEcCtD
Metipranolol—Metoprolol—ABCB1—kidney cancer	0.00192	0.203	CrCbGaD
Metipranolol—Hypersensitivity—Paclitaxel—kidney cancer	0.0019	0.00192	CcSEcCtD
Metipranolol—Dyspnoea—Capecitabine—kidney cancer	0.00189	0.0019	CcSEcCtD
Metipranolol—Visual impairment—Doxorubicin—kidney cancer	0.00185	0.00187	CcSEcCtD
Metipranolol—Asthenia—Paclitaxel—kidney cancer	0.00185	0.00187	CcSEcCtD
Metipranolol—Nausea—Gemcitabine—kidney cancer	0.00183	0.00185	CcSEcCtD
Metipranolol—Propranolol—CYP1A1—kidney cancer	0.00183	0.193	CrCbGaD
Metipranolol—Dizziness—Paclitaxel—kidney cancer	0.0017	0.00172	CcSEcCtD
Metipranolol—Tension—Doxorubicin—kidney cancer	0.00164	0.00166	CcSEcCtD
Metipranolol—Rash—Paclitaxel—kidney cancer	0.00163	0.00164	CcSEcCtD
Metipranolol—Dermatitis—Paclitaxel—kidney cancer	0.00162	0.00164	CcSEcCtD
Metipranolol—Nervousness—Doxorubicin—kidney cancer	0.00162	0.00164	CcSEcCtD
Metipranolol—Headache—Paclitaxel—kidney cancer	0.00161	0.00163	CcSEcCtD
Metipranolol—Vision blurred—Doxorubicin—kidney cancer	0.00157	0.00159	CcSEcCtD
Metipranolol—Hypersensitivity—Capecitabine—kidney cancer	0.00156	0.00157	CcSEcCtD
Metipranolol—Nausea—Paclitaxel—kidney cancer	0.00153	0.00155	CcSEcCtD
Metipranolol—Asthenia—Capecitabine—kidney cancer	0.00152	0.00153	CcSEcCtD
Metipranolol—Palpitations—Doxorubicin—kidney cancer	0.00148	0.00149	CcSEcCtD
Metipranolol—Cough—Doxorubicin—kidney cancer	0.00146	0.00147	CcSEcCtD
Metipranolol—Hypertension—Doxorubicin—kidney cancer	0.00144	0.00146	CcSEcCtD
Metipranolol—Myalgia—Doxorubicin—kidney cancer	0.00142	0.00144	CcSEcCtD
Metipranolol—Anxiety—Doxorubicin—kidney cancer	0.00142	0.00143	CcSEcCtD
Metipranolol—Discomfort—Doxorubicin—kidney cancer	0.00141	0.00142	CcSEcCtD
Metipranolol—Dizziness—Capecitabine—kidney cancer	0.0014	0.00141	CcSEcCtD
Metipranolol—Oedema—Doxorubicin—kidney cancer	0.00136	0.00138	CcSEcCtD
Metipranolol—Rash—Capecitabine—kidney cancer	0.00133	0.00135	CcSEcCtD
Metipranolol—Dermatitis—Capecitabine—kidney cancer	0.00133	0.00135	CcSEcCtD
Metipranolol—Headache—Capecitabine—kidney cancer	0.00133	0.00134	CcSEcCtD
Metipranolol—Nausea—Capecitabine—kidney cancer	0.00126	0.00127	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.00124	0.00125	CcSEcCtD
Metipranolol—Dyspnoea—Doxorubicin—kidney cancer	0.00122	0.00123	CcSEcCtD
Metipranolol—Somnolence—Doxorubicin—kidney cancer	0.00121	0.00122	CcSEcCtD
Metipranolol—Hypersensitivity—Doxorubicin—kidney cancer	0.001	0.00101	CcSEcCtD
Metipranolol—Asthenia—Doxorubicin—kidney cancer	0.000978	0.000988	CcSEcCtD
Metipranolol—Propranolol—ABCB1—kidney cancer	0.00097	0.103	CrCbGaD
Metipranolol—Dizziness—Doxorubicin—kidney cancer	0.000902	0.00091	CcSEcCtD
Metipranolol—Rash—Doxorubicin—kidney cancer	0.00086	0.000868	CcSEcCtD
Metipranolol—Dermatitis—Doxorubicin—kidney cancer	0.000859	0.000867	CcSEcCtD
Metipranolol—Headache—Doxorubicin—kidney cancer	0.000854	0.000862	CcSEcCtD
Metipranolol—Nausea—Doxorubicin—kidney cancer	0.00081	0.000818	CcSEcCtD
